Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

pembrolizumab 301Paclitaxel 206Carboplatin 199Gemcitabine 173Cisplatin 138Docetaxel 137Cyclophosphamide 135Nivolumab 129Bevacizumab 118Injections 111fludarabine 95atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 70Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × tinostamustine × Clear all
NCT02576496 2024-07-25

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Mundipharma Research Limited

Phase 1 Completed
106 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Multiple Myeloma, Lymphoma, T-Cell, Cutaneous, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡